⚠ You're viewing a report from March 2026. Subscribe to get the latest →

FDA Enforcement — March 2026 Report

Automated analysis of 64 items from public government data sources. Updated daily.

Summary

64
Total items
53
High impact
11
Medium impact
0
Low impact

High-impact items this period

Gram Peptides
Internet distribution of unapproved pharmaceutical drugs
Why: Direct-to-consumer online sales of non-approved medications  ·  Mar 31  ·  Impact: HIGH
Guangzhou Huli Technology Co., Ltd. dba Fantasy Face
Internet distribution of unapproved pharmaceutical drugs
Why: Direct-to-consumer online sales of non-approved medications  ·  Mar 31  ·  Impact: HIGH
Lovega LLC dba Pink Pony Peptides
Internet distribution of unapproved pharmaceutical drugs
Why: Direct-to-consumer online sales of non-approved medications  ·  Mar 31  ·  Impact: HIGH
Prime Sciences
Internet distribution of unapproved pharmaceutical drugs
Why: Direct-to-consumer online sales of non-approved medications  ·  Mar 31  ·  Impact: HIGH
FormPour
Internet distribution of unapproved pharmaceutical drugs
Why: Direct-to-consumer online sales of non-approved medications  ·  Mar 31  ·  Impact: HIGH
Mile High Compounds LLC
Internet distribution of unapproved pharmaceutical drugs
Why: Direct-to-consumer online sales of non-approved medications  ·  Mar 31  ·  Impact: HIGH
PekCura Labs
Internet distribution of unapproved pharmaceutical drugs
Why: Direct-to-consumer online sales of non-approved medications  ·  Mar 31  ·  Impact: HIGH
Intas Pharmaceuticals Limited
Finished pharmaceutical products adulterated
Why: Current Good Manufacturing Practice violations in pharmaceutical production  ·  Mar 30  ·  Impact: HIGH
Ehsan Sadri, M.D.
Clinical investigator compliance violations
Why: Failure to comply with clinical trial regulations and protocols  ·  Mar 27  ·  Impact: HIGH
Henan Lvyuan Pharmaceutical Co. Ltd.
CGMP violations in active pharmaceutical ingredient production
Why: Adulterated API from manufacturing process control deficiencies  ·  Mar 26  ·  Impact: HIGH

Selected medium-impact items

Global Tobacco, LLC
Tobacco product adulteration and misbranding violations
Why: Non-compliance with Family Smoking Prevention Control Act  ·  Mar 31  ·  Impact: MEDIUM
buydeltas.com
Tobacco product adulterated and misbranded violations
Why: Violation of Family Smoking Prevention and Tobacco Control Act requirements  ·  Mar 27  ·  Impact: MEDIUM
Winder Laboratories, LLC
Subpotent product: Vitamin D below specification levels
Why: FDA inspection revealed vitamin D content below declared potency  ·  Mar 25  ·  Impact: MEDIUM
Shaman Botanicals, LLC
Active ingredient exceeds labeled specification
Why: Quality control failure in manufacturing process  ·  Mar 25  ·  Impact: MEDIUM
Nupack Inc.
Dietary supplement adulterated or misbranded
Why: Current Good Manufacturing Practice violations in dietary supplement production  ·  Mar 20  ·  Impact: MEDIUM

Get this delivered every week

Free tier: 3 items per vertical. Full access with paid subscription.

Subscribe — $29/mo →

Data sourced from public government APIs. AI analysis via Claude Haiku. Full methodology →